BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huelin P, Solà E, Elia C, Solé C, Risso A, Moreira R, Carol M, Fabrellas N, Bassegoda O, Juanola A, de Prada G, Albertos S, Piano S, Graupera I, Ariza X, Napoleone L, Pose E, Filella X, Morales-Ruiz M, Rios J, Fernández J, Jiménez W, Poch E, Torres F, Ginès P. Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. Hepatology 2019;70:319-33. [PMID: 30810244 DOI: 10.1002/hep.30592] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
Number Citing Articles
1 Gupta K, Bhurwal A, Law C, Ventre S, Minacapelli CD, Kabaria S, Li Y, Tait C, Catalano C, Rustgi VK. Acute kidney injury and hepatorenal syndrome in cirrhosis. World J Gastroenterol 2021; 27(26): 3984-4003 [PMID: 34326609 DOI: 10.3748/wjg.v27.i26.3984] [Reference Citation Analysis]
2 Fang Y, Zhu H, Gao C, Gu Y, Liu Y, Yuan Y, Wu X. Value of shear wave elastography in predicting hepatorenal syndrome in patients with liver cirrhosis and ascites. Int J Clin Pract 2021;75:e14811. [PMID: 34490949 DOI: 10.1111/ijcp.14811] [Reference Citation Analysis]
3 Yi A, Lee CH, Yun YM, Kim H, Moon HW, Hur M. Effectiveness of Plasma and Urine Neutrophil Gelatinase-Associated Lipocalin for Predicting Acute Kidney Injury in High-Risk Patients. Ann Lab Med 2021;41:60-7. [PMID: 32829580 DOI: 10.3343/alm.2021.41.1.60] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yoo JJ, Kwon JH, Kim YS, Nam SW, Park JW, Kim HY, Kim CW, Shin SK, Chon YE, Jang ES, Jeong SH, Lee JW, Song DS, Yang JM, Lee SW, Lee HL, Jung YK, Yim HJ, Lee B, Kim SG, Kim JH. The Role of Urinary N-Acetyl-β-d-glucosaminidase in Cirrhotic Patients with Acute Kidney Injury: Multicenter, Prospective Cohort Study. J Clin Med 2021;10:4328. [PMID: 34640346 DOI: 10.3390/jcm10194328] [Reference Citation Analysis]
5 Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management.BMJ. 2020;370:m2687. [PMID: 32928750 DOI: 10.1136/bmj.m2687] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
6 Sanchez LO, Francoz C. Global strategy for the diagnosis and management of acute kidney injury in patients with liver cirrhosis. United European Gastroenterol J 2021;9:220-8. [PMID: 33337286 DOI: 10.1177/2050640620980713] [Reference Citation Analysis]
7 Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71:811-822. [PMID: 31302175 DOI: 10.1016/j.jhep.2019.07.002] [Cited by in Crossref: 77] [Cited by in F6Publishing: 61] [Article Influence: 25.7] [Reference Citation Analysis]
8 Solé C, Ma AT, Solà E, Carol M, Fabrellas N, Juanola A, Napoleone L, Gratacós-Ginès J, Bassegoda O, Cervera M, Pérez M, Rubio AB, Avitabile E, Morales-Ruiz M, Graupera I, Pose E, Kamath PS, Ginès P. Sequential changes in urinary biomarker levels in patients with cirrhosis and severe hepatorenal syndrome. Liver Int 2021;41:2729-32. [PMID: 34569697 DOI: 10.1111/liv.15069] [Reference Citation Analysis]
9 Tariq R, Singal AK. Management of Hepatorenal Syndrome: A Review. J Clin Transl Hepatol 2020;8:192-9. [PMID: 32832400 DOI: 10.14218/JCTH.2020.00011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
10 Türe E, Yazar A, Akın F, Topcu C, Aydın A, Balasar M, Ataş B. Early kidney injury in immunoglobulin A vasculitis: Role of renal biomarkers. Pediatr Int 2021;63:1218-22. [PMID: 33423326 DOI: 10.1111/ped.14600] [Reference Citation Analysis]
11 Kim TH, Seo YS, Kang SH, Kim MY, Kim SG, Lee HY, Lee JH, Lee YS, Kim JH, Jeong SW, Jang JY, Suk KT, Jung YK, An H, Yim HJ, Kim YS, Um SH;  Korean Study Group of Portal Hypertension. Prognosis predictability of serum and urine renal markers in patients with decompensated cirrhosis: A multicentre prospective study. Liver Int. 2020;40:3083-3092. [PMID: 32750739 DOI: 10.1111/liv.14631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Liu S, Meng Q, Xu Y, Zhou J. Hepatorenal syndrome in acute-on-chronic liver failure with acute kidney injury: more questions requiring discussion. Gastroenterol Rep (Oxf) 2021;9:505-20. [PMID: 34925848 DOI: 10.1093/gastro/goab040] [Reference Citation Analysis]
13 Simbrunner B, Trauner M, Reiberger T, Mandorfer M. Recent advances in the understanding and management of hepatorenal syndrome. Fac Rev 2021;10:48. [PMID: 34131658 DOI: 10.12703/r/10-48] [Reference Citation Analysis]
14 Basthi Mohan P, Nagaraju SP, Rangaswamy D, Musunuri B, Prabhu Attur R, Bhat G, Shailesh, Shetty S. Urinary neutrophil gelatinase-associated lipocalin: Acute kidney injury in liver cirrhosis. Clin Chim Acta 2021;523:339-47. [PMID: 34666028 DOI: 10.1016/j.cca.2021.10.015] [Reference Citation Analysis]
15 Jones BE, Allegretti AS, Pose E, Mara KC, Ufere NN, Avitabile E, Shah VH, Kamath PS, Ginès P, Simonetto DA. Renal Replacement Therapy for Acute Kidney Injury in Severe Alcohol-Associated Hepatitis as a Bridge to Transplant or Recovery. Dig Dis Sci 2021. [PMID: 33604793 DOI: 10.1007/s10620-021-06864-z] [Reference Citation Analysis]
16 Patidar KR, Adibuzzaman M, Naved MA, Rodriquez D, Slaven JE, Grama A, Desai AP, Gomez EV, Ghabril MS, Nephew L, Samala NR, Anderson M, Chalasani NP, Orman ES. Practice patterns and outcomes associated with intravenous albumin in patients with cirrhosis and acute kidney injury. Liver Int 2022;42:187-98. [PMID: 34779104 DOI: 10.1111/liv.15096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Liu H, Zhu P, Nie C, Ye Q, Gao Y, Liu H, Pang G, Han T. The value of ascitic neutrophil gelatinase-associated lipocalin in decompensated liver cirrhosis with spontaneous bacterial peritonitis. J Clin Lab Anal 2020;34:e23247. [PMID: 32100329 DOI: 10.1002/jcla.23247] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Mauro E, Garcia-Olveira L, Gadano A. End-stage liver disease: Management of hepatorenal syndrome. Liver Int 2021;41 Suppl 1:119-27. [PMID: 34155791 DOI: 10.1111/liv.14866] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Hiramine Y, Uto H, Mawatari S, Kanmura S, Imamura Y, Hiwaki T, Saishoji A, Oku M, Tokushige K, Maenohara S, Ido A. Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites. J Gastroenterol 2021;56:54-66. [PMID: 32959093 DOI: 10.1007/s00535-020-01727-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Velez JCQ, Therapondos G, Juncos LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.Nat Rev Nephrol. 2020;16:137-155. [PMID: 31723234 DOI: 10.1038/s41581-019-0218-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
21 Velez JCQ. Hepatorenal Syndrome Type 1: From Diagnosis Ascertainment to Goal-Oriented Pharmacologic Therapy. Kidney360 2022;3:382-95. [PMID: 35373127 DOI: 10.34067/KID.0006722021] [Reference Citation Analysis]
22 Lumlertgul N, Amprai M, Tachaboon S, Dinhuzen J, Peerapornratana S, Kerr SJ, Srisawat N. Urine Neutrophil Gelatinase-associated Lipocalin (NGAL) for Prediction of Persistent AKI and Major Adverse Kidney Events. Sci Rep 2020;10:8718. [PMID: 32457335 DOI: 10.1038/s41598-020-65764-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]